Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals

2017-09-01
Price :
Published : Sep-2017
No. of Pages : 77

Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals

Summary

GlobalData’s “Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals”, report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry reported a decrease in the number of deals and deal values in July 2017. The industry reported 314 deals worth USD29.5 billion in July 2017, compared to 392 deals worth USD31.5 billion in June 2017. The oncology therapeutics market remained at the top in deal activity in July 2017 with 104 deals. In second place, infectious disease therapeutics market reported 60 deals. Licensing agreements in pharmaceutical and healthcare industry registered an increase in upfront payments. The segment reported USD203.7m as upfront payments in July 2017, compared to USD130m in June 2017. The number of deals in North America decreased to 203 in July 2017 from 254 in June 2017.

Scope

– Analysis of the market trends for the pharmaceutical industry in the global arena.
– Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women’s health segments.
– Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
– Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
– Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
– Analysis of partnership and licensing deals based on clinical stage of development of products.
– Summary of the pharmaceutical deals globally in the six months.
– Information on the top deals happened in the pharmaceutical industry.
– Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
– League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

– Enhance your decision making capability in a more rapid and time sensitive manner.
– Find out the major deal performing segments for investments in your industry.
– Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
– Identify companies that are aggressively looking to raise capital in the market
– Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
– Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
– Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
– Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
– Identify growth segments and opportunities in each region within the industry.
– Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Digital Landscape: Inflammatory Bowel Disease

Digital Landscape: Inflammatory Bowel Disease Summary The Digital Landscape Inflammatory Bowel Disease report analyzes digital activities undertaken by pharma in support of disease-modifying therapies for mild-to-moderate, and moderate-to-severe Crohn's disease and ulcerative colitis (UC). Key Highlights - US Patients: AbbVie offers the strongest support for IBD patients in the US, particularly branded, unbranded and mobile app. Janssen was the most active competitor in the branded and social media spaces in 2017. Branded activity also seen from pipeline and biosimilar competitors. No IBD-specific mobile apps detected from pharma. Opportunity exists for a well-integrated unbranded campaign to support patients, linked to social media and a mobile app. - US HCPs: Good support av......
$6000

Healthcare Industry Business Outlook and Procurement Report July 2018 – December 2018

Healthcare Industry Business Outlook and Procurement Report July 2018 - December 2018 Summary GlobalData's "Healthcare Industry Business Outlook and Procurement Report July 2018 - December 2018", examines executives' opinions on the business outlook and procurement activities over July-December 2018. Organizations can know about key business priorities, changes in capital expenditure, global revenue contributors, and key information about the organizations' digital transformation strategies along with investment in emerging technologies. Additionally, it provides information categorized by region and company types. The highest percentages of healthcare industry executives identify expansion in the current market and new product development as the foremost priorities of healthcare ......
$1950

House Dust Mite Allergy Global Clinical Trials Review, H2, 2018

House Dust Mite Allergy Global Clinical Trials Review, H2, 2018 Summary GlobalData's clinical trial report, "House Dust Mite Allergy Global Clinical Trials Review, H2, 2018" provides an overview of House Dust Mite Allergy clinical trials scenario. This report provides top line data relating to the clinical trials on House Dust Mite Allergy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500

Kidney Transplant Rejection Global Clinical Trials Review, H2, 2018

Kidney Transplant Rejection Global Clinical Trials Review, H2, 2018 Summary GlobalData's clinical trial report, "Kidney Transplant Rejection Global Clinical Trials Review, H2, 2018" provides an overview of Kidney Transplant Rejection clinical trials scenario. This report provides top line data relating to the clinical trials on Kidney Transplant Rejection. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary......
$2500

Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027

Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027 Summary ALS is a rare but fatal progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord (Doi et al., 2014). ALS is often referred to as "Lou Gehrig's Disease" after the famous baseball player. ALS severely impacts physical functioning, and initially presents with muscle twitching, weakness in an arm or leg, or sometimes with slurring of speech. Eventually, people with ALS lose their ability to control the muscles needed to move, speak, eat, and breathe, which ultimately leads to death. GlobalData epidemiologists used age- and sex-specific diagnosed prevalence rates to forecast the diagnosed prevalent cases, and used the diagnosis rate and diagnosed prevalence to calculate total......
$3995

Self Testing – Medical Devices Pipeline Assessment, 2018

Self Testing - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Self Testing - Medical Devices Pipeline Assessment, 2018" provides an overview of Self Testing currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Self Testing pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry e......
$2500

Hemostasis Rapid Tests & Point of Care (POC) – Medical Devices Pipeline Assessment, 2018

Hemostasis Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Hemostasis Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2018" provides an overview of Hemostasis Rapid Tests & Point of Care (POC) currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hemostasis Rapid Tests & Point of Care (POC) pipeline products. This ......
$2500

Hematology Reagents – Medical Devices Pipeline Assessment, 2018

Hematology Reagents - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Hematology Reagents - Medical Devices Pipeline Assessment, 2018" provides an overview of Hematology Reagents currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hematology Reagents pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by Glo......
$2500

Anemia Tests – Medical Devices Pipeline Assessment, 2018

Anemia Tests - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Anemia Tests - Medical Devices Pipeline Assessment, 2018" provides an overview of Anemia Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Anemia Tests pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry e......
$2500

Hematology Analyzers – Medical Devices Pipeline Assessment, 2018

Hematology Analyzers - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Hematology Analyzers - Medical Devices Pipeline Assessment, 2018" provides an overview of Hematology Analyzers currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hematology Analyzers pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy